Neurobiology of Lipids Noteworthy Articles

Noteworthy section of the Neurobiology of Lipids (ISSN 1683-5506) alerts interested readers about the selected noteworthy original research and viewpoint/review articles, book reviews, and meeting reports (published in other journals) on the subject of the journal scope

NoL Home | Noteworthy home | NoL Content | Archiving your research in NoL is a new service by the Neurobiology of Lipids NoL archives your research | Mission | PubMed | IFORA | Affiliates  | Contact us
For Graduate students: Assistant Editor and Research Assistant Opportunities

October 5, 2007

Role of HMG-CoA Reductase Inhibitors in Neurological Disorders : Progress to Date

Write to authors to ask them to make this article freely available at NoL Archive

Drugs. 2007;67(15):2111-20
Reiss AB, Wirkowski E.
SUNY Stony Brook School of Medicine, Vascular Biology Institute, Winthrop-University Hospital, Mineola, New York, USA


Inhibitors of HMG-CoA reductase (statins) are cholesterol-lowering agents that dramatically reduce morbidity and mortality in patients with established cardiovascular disease. In addition, they exhibit pleiotropic effects that operate independently of lipid modification. Statin administration results in greater nitric oxide bioavailability, improved endothelial function, enhanced cerebral blood flow, immune modulation with anti-inflammatory action, decreased platelet aggregation and antioxidant activity. Some or all of these effects may improve outcome or ameliorate symptoms in neurological disorders. This article examines the potential role of statins in treating stroke, Alzheimer's disease, multiple sclerosis and Parkinson's disease. Studies are ongoing in this controversial area, but there are no firm conclusions. The appropriateness of initiating statin therapy for neurological disorders is not established at this time. The exception is stroke, in which recurrence is significantly reduced by statin therapy.

PubMed ID and Record

0 Comments:

Post a Comment

<< Home